|
Targacept Begins Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes
Trading Markets (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News